CaliPharms, Inc.
Other OTCTotal Valuation
CaliPharms, Inc. carries a market capitalization of 474,349.00, placing it among publicly traded companies globally.
| Market Cap | 474,349.00 |
| Enterprise Value | N/A |
Share Statistics
CaliPharms, Inc. currently has 3.36B shares outstanding.
| Shares Outstanding | 3.36B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 14.25, and the price-to-book ratio stands at -0.05.
| PE Ratio | N/A |
| PS Ratio | 14.25 |
| PB Ratio | -0.05 |
| P/TBV Ratio | -0.18 |
| P/FCF Ratio | -2.28 |
| P/OCF Ratio | -2.28 |
Financial Position
CaliPharms, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -0.32 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -86,279.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
CaliPharms, Inc.'s stock has gained approximately 3900% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 3900% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CaliPharms, Inc. generated 112,465.00 in revenue and converted that into -6.39M in net income, yielding earnings per share of 0.00. EBITDA reached -822,166.00, while operating income came in at -822,166.00.
| Revenue | 112,465.00 |
| Gross Profit | -30,566.00 |
| Operating Income | -822,166.00 |
| Pretax Income | -6.39M |
| Net Income | -6.39M |
| EBITDA | -822,166.00 |
| EBIT | -822,166.00 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Total book value stands at -33.94M, with working capital of -8.79M providing operational flexibility.
| Cash & Cash Equivalents | 17,162.00 |
| Total Debt | N/A |
| Net Debt | 205,392.00 |
| Equity (Book Value) | -33.94M |
| Book Value Per Share | -0.01 |
| Working Capital | -8.79M |
Cash Flow
CaliPharms, Inc. produced -703,063.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -703,063.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -703,063.00 |
| FCF Per Share | 0.00 |
Margins
CaliPharms, Inc. operates with a gross margin of -27.18, reflecting its pricing power and cost economics. The operating margin of -731.04 and net profit margin of -5,677.83 provide insight into operational efficiency.
| Gross Margin | -27.18 |
| Operating Margin | -731.04 |
| Pretax Margin | -5,677.83 |
| Profit Margin | -5,677.83 |
| EBITDA Margin | -731.04 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -47.27 |
| FCF Yield | -43.87 |
Stock Splits
CaliPharms, Inc.'s most recent stock split took place on July 19, 2013 with a 2000:1 split ratio.
| Last Split Date | 7/19/2013 |
| Split Ratio | 2000:1 |
Scores
CaliPharms, Inc. posts an Altman Z-Score of -3,534.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3,534.72 |